Company Encyclopedia
View More
name
Lucid Diagnostics
LUCD.US
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients.
1.399 T
LUCD.USMarket value -Rank by Market Cap -/-

Financial Score

23/12/2025 Update
C
Health Care EquipmentIndustry
Industry Ranking80/174
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE168.79%A
    • Profit Margin-1211.30%E
    • Gross Margin-40.13%E
  • Growth ScoreC
    • Revenue YoY5.01%C
    • Net Profit YoY-25.86%D
    • Total Assets YoY135.41%A
    • Net Assets YoY307.62%A
  • Cash ScoreC
    • Cash Flow Margin-6.68%D
    • OCF YoY5.01%C
  • Operating ScoreE
    • Turnover0.12E
  • Debt ScoreC
    • Gearing Ratio51.44%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Lucid Diagnostics shares are trading higher after the company reported real-world data showing a 95% technical success rate for EsoGuard procedures, most completed in under two minutes with no serious adverse events.

    benzinga_article·
    US
    LUCD
    +0.89%
    benzinga_article·
    US
    LUCD
    +0.89%

    Lucid Diagnostics reports positive data from largest real-world experience of esophagal precancer detection with 12,000 patients.

    A study analyzed data from around 12,000 patients who took Lucid's EsoGuard® Esophageal DNA Test with samples collected through its EsoCheck® Esophageal Cell Collection Device. The findings showcased the test's strong technical performance, quick cell-collection process, and appropriate utilization by physicians.

    Unusual Whales·
    US
    LUCD
    +0.89%
    Unusual Whales·
    US
    LUCD
    +0.89%

    Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree | LUCD Stock News

    Lucid Diagnostics Inc., a cancer prevention medical diagnostics company, has been named a top-ranking honoree in the GenomeWeb 2025 Best Places to Work program. This recognition highlights Lucid's commitment to a positive workplace culture, emphasizing transparent communication, inclusivity, and professional development. The company focuses on early detection of esophageal precancer in patients with GERD. Lucid's President, Shaun O'Neil, attributes this honor to the dedication of their team. The announcement also includes forward-looking statements about the company's future operations and market conditions.

    StockTitan·
    US
    LUCD
    +0.89%
    StockTitan·
    US
    LUCD
    +0.89%

    Lucid Diagnostics (LUCD) Receives a Buy from Cantor Fitzgerald

    Cantor Fitzgerald's Ross Osborn reiterated a Buy rating for Lucid Diagnostics (LUCD) with a $3.00 price target, while the stock closed at $1.05. The analyst consensus suggests a Strong Buy with a $3.75 average price target, indicating a 257.14% potential upside. Needham also maintained a Buy rating with a $3.00 target.

    Tip Ranks·
    US
    LUCD
    +0.89%
    Tip Ranks·
    US
    LUCD
    +0.89%

    Lucid Diagnostics: Buy Rating Backed by Strong Growth, Financial Stability, and Strategic Expansion

    Analyst Anthony Vendetti from Maxim Group maintains a Buy rating on Lucid Diagnostics with a $3.00 price target, citing strong growth, financial stability, and strategic expansion. Lucid Diagnostics shows steady growth in testing volumes and is financially well-positioned, aiming to expand Medicare and private insurance coverage. Anticipated Medicare coverage approval by 2025 is a key catalyst. Canaccord Genuity also maintains a Buy rating with the same price target. LUCD's stock price increased by 0.91% over six months.

    Tip Ranks·
    US
    LUCD
    +0.89%
    Tip Ranks·
    US
    LUCD
    +0.89%
    © 2025 Longbridge｜Disclaimer